In Wake of COVID Shot Being Added to CDC's Childhood Immunization Schedule, We The Patriots USA Seeks to Make Vaccination Status Discrimination Illegal
20 oct. 2022 16h46 HE
|
We The Patriots USA, Inc.
ATLANTA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- The following is an open letter from We The Patriots USA, Inc.: Just hours ago, the Centers for Disease Control and Prevention (CDC)'s Advisory Committee...
Global Albumin Market Projected to Beat $10,239.0 Million, Growing with a CAGR of 6.1% in the 2022-2032 Timeframe [250-Pages] | Conclusion by Research Dive
11 oct. 2022 09h07 HE
|
Research Dive
New York, USA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Research Dive has published a new report on the global albumin market. As per the report, the market is anticipated to garner $10,239.0 million and...
Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
06 oct. 2022 08h00 HE
|
Ocugen
MALVERN, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
04 oct. 2022 08h00 HE
|
Vir Biotechnology, Inc.
– First award from the agency’s solicitation for contracts for Pre-Exposure Prophylaxis for Influenza – – Initial investment of approximately $55 million from Biomedical Advanced Research and...
Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
28 sept. 2022 06h30 HE
|
Ocugen
Ocugen’s intranasal candidate is one of the world’s most advanced intranasal COVID-19 vaccinesIntranasal vaccine is designed to curb virus transmission and confer protective immunity MALVERN, Pa.,...
POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19
20 sept. 2022 21h31 HE
|
POP Biotechnologies, Inc.
BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of...
With 8.8 % CAGR, Influenza Vaccine Market Size worth USD 13.58 billion by 2029
13 sept. 2022 06h14 HE
|
Fortune Business Insights
Pune, India, Sept. 13, 2022 (GLOBE NEWSWIRE) -- The global influenza vaccine market size was USD 7.02 billion in 2021 and USD 7.54 billion in 2022. It is anticipated to reach USD 13.58 billion by...
BioNTech CEO Ugur Sahin besuchte Israel: Diskussion möglicher Zusammenarbeit bei der Pandemievorsorge und der Entwicklung innovativer Medikamente
07 sept. 2022 02h00 HE
|
BioNTech SE
JERUSALEM, Israel, und MAINZ, Deutschland, 7. September 2022 — BioNTech SE (Nasdaq: BNTX, „BioNTech“) gab heute bekannt, dass Prof. Ugur Sahin, CEO und Mitbegründer von BioNTech, nach Israel gereist...
BioNTech CEO Ugur Sahin Visited Israel to Discuss Cooperation on Pandemic Preparedness and the Development of Innovative Medicines
07 sept. 2022 02h00 HE
|
BioNTech SE
JERUSALEM, Israel, and MAINZ, Germany, September 7, 2022 —BioNTech SE (Nasdaq: BNTX) announced today that Prof. Ugur Sahin, CEO and Co-founder of BioNTech, visited Israel to meet with the Minister of...
HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series
01 sept. 2022 17h18 HE
|
HilleVax, Inc.
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...